Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial

Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, View ORCID ProfileDiego Rodrigues Falci, Elias Sarkis, Joel Solis, Hanzhe Zheng, Nicola Scott, Andrea L. Cathcart, Sergio Parra, Jennifer E. Sager, View ORCID ProfileDaren Austin, Amanda Peppercorn, Elizabeth Alexander, Wendy W. Yeh, Cynthia Brinson, Melissa Aldinger, View ORCID ProfileAdrienne E. Shapiro
doi: https://doi.org/10.1101/2021.11.03.21265533
Anil Gupta
1Albion Finch Medical, William Osler Health Centre, Toronto, Ontario, Canada
MD, CCFP, FCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaneicy Gonzalez-Rojas
2Optimus U, Corp., Miami, Florida, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erick Juarez
3Florida International Medical Research, Miami, Florida, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Crespo Casal
4Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Pontevedra, Spain
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaynier Moya
5Pines Care Research Center, Pembroke Pines, Florida, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego Rodrigues Falci
6Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diego Rodrigues Falci
Elias Sarkis
7Sarkis Clinical Trials, Gainesville, Florida, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Solis
8Centex Studies, McAllen, Texas, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanzhe Zheng
9Vir Biotechnology, Inc., San Francisco, California, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Scott
10GlaxoSmithKline, Brentford, United Kingdom
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea L. Cathcart
9Vir Biotechnology, Inc., San Francisco, California, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Parra
9Vir Biotechnology, Inc., San Francisco, California, USA
MD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer E. Sager
9Vir Biotechnology, Inc., San Francisco, California, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daren Austin
10GlaxoSmithKline, Brentford, United Kingdom
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daren Austin
Amanda Peppercorn
11GlaxoSmithKline, Cambridge, Massachusetts, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Alexander
9Vir Biotechnology, Inc., San Francisco, California, USA
MD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy W. Yeh
9Vir Biotechnology, Inc., San Francisco, California, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Brinson
12Central Texas Clinical Research, Austin, Texas, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Aldinger
9Vir Biotechnology, Inc., San Francisco, California, USA
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne E. Shapiro
13Departments of Global Health and Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adrienne E. Shapiro
  • For correspondence: aeshapir@uw.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Older patients and those with underlying comorbidities infected with SARS-CoV-2 may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a neutralizing antibody designed for treatment of high-risk patients to prevent COVID-19 progression.

Objective To evaluate the efficacy and safety of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease.

Design Randomized, double-blind, multicenter, placebo-controlled, phase 3 study.

Setting 57 centers in 5 countries.

Participants Nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for disease progression.

Intervention Patients were randomized (1:1) to an intravenous infusion of sotrovimab 500 mg or placebo.

Main Outcomes and Measures The primary efficacy outcome was the proportion of patients with COVID-19 progression, defined as all-cause hospitalization longer than 24 hours for acute illness management or death through day 29. Key secondary outcomes included the proportion of patients with COVID-19 progression, defined as emergency room visit, hospitalization of any duration, or death, and proportion of patients developing severe/critical respiratory COVID-19 requiring supplemental oxygen.

Results Among 1057 patients randomized (sotrovimab, 528; placebo, 529), all-cause hospitalization longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) by 79% (95% CI, 50% to 91%; P<.001). Secondary outcome results further demonstrated the effect of sotrovimab in reducing emergency room visits, hospitalization of any duration, or death, which was reduced by 66% (95% CI, 37% to 81%; P<.001), and severe/critical respiratory COVID-19, which was reduced by 74% (95% CI, 41% to 88%; P=.002). No patients receiving sotrovimab required high-flow oxygen, oxygen via nonrebreather mask, or mechanical ventilation compared with 14 patients receiving placebo. The proportion of patients reporting adverse events was similar between treatment groups; sotrovimab was well tolerated, and no safety concerns were identified.

Conclusions and Relevance Among nonhospitalized patients with mild to moderate COVID-19, a single 500-mg intravenous dose of sotrovimab prevented progression of COVID-19, with a reduction in hospitalization and need for supplemental oxygen. Sotrovimab is a well-tolerated, effective treatment option for patients at high risk for severe morbidity and mortality from COVID-19.

Trial Registration ClinicalTrials.gov Identifier: NCT04545060

Competing Interest Statement

Drs Gupta, Gonzalez-Rojas, Juarez, Crespo Casal, Moya, Solis, and Shapiro report acting as trial investigators for Vir Biotechnology and receiving non-financial support from Vir Biotechnology during the conduct of the study. Dr Rodrigues Falci reports acting as a trial investigator for Vir Biotechnology and receiving nonfinancial support from Vir Biotechnology during the conduct of the study, and personal fees and nonfinancial support from Pfizer and United Medical, nonfinancial support from Gilead Sciences and Merck Sharp & Dohme, and personal fees from GlaxoSmithKline outside the submitted work. Dr Sarkis reports acting as a trial investigator for Vir Biotechnology and receiving nonfinancial support from Vir Biotechnology during the conduct of the study; research support from AbbVie, Eli Lilly, GlaxoSmithKline, Otsuka, Vir Biotechnology, Eisai, and Ironshore; and serving on speaker bureaus for Janssen, Teva, and AbbVie. Drs Zheng, Parra, Sager, Alexander, Yeh, and Aldinger are employees of Vir Biotechnology and report stock ownership in Vir Biotechnology and third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work. Ms Scott, Dr Austin, and Dr Peppercorn are employees of GlaxoSmithKline and report stock ownership in GlaxoSmithKline. Dr Cathcart is an employee of Vir Biotechnology and reports stock ownership in Vir Biotechnology, third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work, and stock ownership in Gilead Sciences outside the submitted work. Dr Brinson reports acting as a trial investigator for Vir Biotechnology and receiving nonfinancial support from Vir Biotechnology during the conduct of the study, and personal fees for advisory boards and speakers bureaus from Gilead Sciences and ViiV Healthcare outside the submitted work.

Clinical Trial

NCT04545060

Funding Statement

This study was sponsored by Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the following ethics review boards: Research Ethical Committee of the Universidade De Passo Fundo/Office Of The Assistant Dean Of Research And Graduate Studies, Brazil (454545/249305), Research Ethical Committee of the Liga Norte Riograndense Contra O Cancer, Brazil (356987/249067), Comite de Etica em Pesquisa do Hospital Leforte, Brazil (454407/249306; 454407/249306), Research ethical Committee of the Hospital de Clinicas de Porto Alegre of the Federal University of Rio Grande do Sul, Brazil (412641/249076), Research Ethical Committee of the Brotherhood of the Holy House of Mercy of Porto Alegre, Brazil (452132/249278), Advarra, Canada (125285/249219; 233252/249074), Comite Nacional Transitorio de Etica en Investigacion para la evaluacion y supervision eticas de los Ensayos Clinicos de la enfermedad COVID-19 (CNTEI COVID-19), Peru (453319/249281), CEIm Corporacio Sanitaria Parc Tauli Parque del Tauli, Spain (466003/249291; 010074/249923; 230601/249242), Advarra, United States (316647/249611; 393090/249560; 320687/249555; 427380/249631; 093073/249546; 449583/248364; 009334/249320; 021490/248894; 457707/249681; 076115/248362; 457712/249682; 354044/249803; 171466/248900; 458530/249910; 457765/249683; 408728/249251; 458692/249844; 176292/249239; 006879/248345; 347052/249553; 455576/249387; 455582/249389; 456034/249493; 053521/249195; 455575/249386; 028996/249554; 458529/249909; 370717/249241; 331745/249072; 453800/249220; 459369/249998; 429263/248346; 455578/249390; 457328/249637; 259973/249632; 023446/249253; 457766/249684; 456703/249634; 014897/248899; 306670/249073; 306670/249073; 007907/250048; 373940/248347; 419336/249556; 455826/249420.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will serve as a basis for a regulatory filing and cannot be shared at this time.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Diego Rodrigues Falci, Elias Sarkis, Joel Solis, Hanzhe Zheng, Nicola Scott, Andrea L. Cathcart, Sergio Parra, Jennifer E. Sager, Daren Austin, Amanda Peppercorn, Elizabeth Alexander, Wendy W. Yeh, Cynthia Brinson, Melissa Aldinger, Adrienne E. Shapiro
medRxiv 2021.11.03.21265533; doi: https://doi.org/10.1101/2021.11.03.21265533
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Diego Rodrigues Falci, Elias Sarkis, Joel Solis, Hanzhe Zheng, Nicola Scott, Andrea L. Cathcart, Sergio Parra, Jennifer E. Sager, Daren Austin, Amanda Peppercorn, Elizabeth Alexander, Wendy W. Yeh, Cynthia Brinson, Melissa Aldinger, Adrienne E. Shapiro
medRxiv 2021.11.03.21265533; doi: https://doi.org/10.1101/2021.11.03.21265533

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)